Molbio Diagnostics Limited
MainboardMOLBIO • BSE, NSE
Issue details
Price band
₹768 - ₹807
Lot size
18 shares
Issue size
₹658.39 Cr
Min. investment
₹14,526
Registrar
KFin Technologies
Subscription
43.07x
Grey market premium
Est. gain+₹120 · 15%
Save your family's PANs once and check allotment for everyone the moment results are out.
Sign in with a mobile OTP. It takes 20 seconds.
IPO Timeline
Open
10 Aug
Close
12 Aug
Allotment
13 Aug
Listing
17 Aug
- Refunds & demat credit
- 14 Aug 2026
- Mandate end
- 27 Aug 2026
- Anchor lock-in 50%
- 12 Sep 2026
- Anchor lock-in 100%
- 11 Nov 2026
We calculate these dates from the allotment and close dates, so please treat them as indicative. Anchor lock-in applies only to issues with an anchor allotment.
Application size
| Category | Minimum | Maximum |
|---|---|---|
| RII | 18shares 1 lot · ₹14,526 | 234shares 13 lots · ₹1,88,838 |
| sNII (₹2L–₹10L) | 252shares 14 lots · ₹2,03,364 | 1,224shares 68 lots · ₹9,87,768 |
| bNII (above ₹10L) | 1,242shares 69 lots · ₹10,02,294 | No limit funds permitting |
Based on the upper price band of ₹807 and a lot of 18 shares.
Subscription
| Quota | Shares offered | Shares bid | Subscribed |
|---|---|---|---|
| NII | 17,43,860 | 6,16,41,990 | 35.35x |
| bNII (above ₹10L) | 5,81,286 | 1,91,90,376 | 33.01x |
| Retail (IND) | 40,69,005 | 3,69,38,736 | 9.08x |
| Total | 81,58,529 | 35,13,76,254 | 43.07x |
Last updated 75 days ago.
Issue structure
Face value
₹1 per share
Issue type
Bookbuilding IPO
Sale type
Fresh capital cum OFS
Fresh issue
₹200 Cr
24,80,246 shares
Offer for sale
₹740 Cr
91,66,000 shares
Shares pre-issue
11,27,59,750
Shares post-issue
11,52,39,996
Valuation & ratios
| Metric | Pre-IPO | Post-IPO |
|---|---|---|
| EPS | 14.56 | 14.24 |
| P/E | 55.43 | 56.67 |
| Market cap | ₹9,099.71 Cr. | ₹12,004.55 Cr |
| KPI | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| ROE | 15.59% | 16.20% |
| ROCE | 17.55% | 20.98% |
| RoNW | 14.55% | 15.23% |
| PAT Margin | 11.28% | 13.48% |
| EBITDA Margin | 22.56% | 24.97% |
| NAV | 101.51 | 84.51 |
| Price to Book Value | — | 9.55 |
Financials
| Metric | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Total income | 1,455.17 | 1,027.94 | 840.66 |
| Profit after tax | 164.14 | 138.58 | 83.54 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| Net worth | 1,144.68 | 952.95 | 807.94 |
| Assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Reserves & surplus | 1,148.84 | 990.84 | 845.48 |
| Total borrowing | 412.64 | 123.16 | 174.58 |
Figures in ₹ crore, as reported by the company in its offer document.
Objects of the issue
- 1.Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space.₹105.54 Cr
- 2.Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and₹72.28 Cr
- 3.General Corporate Purposes₹9.47 Cr
- 4.Issue Expenses₹59.54 Cr
What the company says it intends to do with the money raised.
Recent comparable IPOs
| Company | Issue price | P/E | Listing close | Listing gain |
|---|---|---|---|---|
| Fabtech Technologies Ltd.Mainboard | ₹191 | 13.32 | ₹182.40 | -4.50% |
| Q-Line Biotech Ltd.SME | ₹343 | 20.82 | ₹474.60 | +38.37% |
| Earkart Ltd.SME | ₹135 | 20.48 | ₹142.25 | +5.37% |
| Galaxy Medicare Ltd.SME | ₹54 | 19.01 | ₹51.30 | -5.00% |
Past listing performance of comparable issues. This is not a forecast: listing gains vary widely and can turn negative.
Issue fundamentals compiled from the company's offer document via Chittorgarh, last read 27 Sep 2026. Always verify against the RHP before applying.